Incannex Announces Positive Results from Phase 2 Psi-GAD1 Trial of Psilocybin
Fortrea has inked a deal with Australia’s Incannex Healthcare to manage investigative new drug (IND) clinical trials for a cannabinoid-based treatment for obstructive sleep apnea.
Incannex Healthcare Ltd., a clinical-stage pharmaceutical company developing medicinal cannabinoid and psychedelic therapies for unmet medical needs, has engaged CDMO Eurofins Scientific to manufacture ReneCann therapeutic for topical applications.
Incannex, Eurofins Enter Development & Mfg. Pact for Addiction Disorder Meds
Clinical-stage pharmaceutical company Incannex Healthcare (ASX: IHL) has engaged French organisation Eurofins Scientific to manufacture its medicated chewable products designed to treat nicotine and opioid addiction disorders.
Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) has engaged leading contract research, development and manufacturing company Curia Global Inc to develop and manufacture GMP-grade IHL-216A, its proprietary inhaled drug for the treatment of concussion and traumatic brain injury.
Clinical stage pharmaceutical development company, Incannex Healthcare Limited (ASX: IHL) (NASDAQ: IXHL), ('Incannex' or the 'Company'), is pleased...
MELBOURNE, Australia, July 21, 2022 /PRNewswire/ -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), ('Incannex' or the 'Company') a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical needs, is pleased to announce that it has received approval from the Bellberry Human Research Ethics Committee ('HREC') for a phase 1 clinical trial investigating its proprietary multi-use, anti-inflammatory drug IHL-675A.
Incannex Healthcare Limited (NASDAQ: IXHL) (ASX: IHL), ('Incannex' or the 'Company') a clinical-stage pharmaceutical company developing unique...
Incannex Healthcare Limited (NASDAQ: IXHL) (ASX: IHL), ('Incannex' or the 'Company') a clinical-stage pharmaceutical company developing unique...